Smith & Nephew (LON:SN) Sets New 52-Week High – Still a Buy?

Smith & Nephew plc (LON:SN)’s stock price hit a new 52-week high during mid-day trading on Friday . The company traded as high as GBX 1,250.50 and last traded at GBX 1,248, with a volume of 1196793 shares traded. The stock had previously closed at GBX 1,240.50.

Analyst Upgrades and Downgrades

SN has been the topic of several recent research reports. Berenberg Bank restated a “hold” rating and set a GBX 1,300 target price on shares of Smith & Nephew in a report on Friday, January 23rd. Panmure Gordon reissued a “hold” rating and set a GBX 1,200 price objective on shares of Smith & Nephew in a report on Tuesday, December 9th. Finally, Royal Bank Of Canada downgraded Smith & Nephew to a “sector perform” rating and cut their price objective for the company from GBX 1,700 to GBX 1,350 in a research note on Wednesday, December 17th. Two research analysts have rated the stock with a Buy rating and four have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Smith & Nephew currently has a consensus rating of “Hold” and an average price target of GBX 1,381.33.

Smith & Nephew Stock Up 0.6%

The stock has a market cap of £13.68 billion, a P/E ratio of 44.93, a P/E/G ratio of 0.46 and a beta of 0.68. The company has a current ratio of 2.57, a quick ratio of 0.84 and a debt-to-equity ratio of 62.90. The firm’s fifty day moving average is GBX 1,272.11 and its 200 day moving average is GBX 1,298.34.

Smith & Nephew Company Profile

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.